Metabolic control with insulin pump therapy: The Waikato experience

New Zealand Medical Journal

Volumn 120, Issue 1248, 2007, Pages

  Reda, Elham ^a   Von Reitzenstein, Angelica ^a   Dunn, Peter ^a  

^a WAIKATO HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AWARENESS; CHILD; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INJECTION SITE INFECTION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NEW ZEALAND; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INFUSION PUMP; MEDICAL AUDIT; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INSULIN; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 33846849613     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
2. Kostraba JN, Dorman J, Sorchard TJ, et al. Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care. 1989;12:686-93.
3. Shalitin S, Josefsberg Z, Lilos P, et al. Bedside scoring procedure for the diagnosis of diabetic peripheral neuropathy in young patients with Type 1 diabetes. J Pediatr Endocrinol Metab. 2002;15:613-20.
4. Mecklenburg RS. Insulin-pump therapy. In: Therapy for Diabetes Mellitus and Related disorders. 3rd Ed. Lebovitz H, Ed. Alexandria VA: American Diabetes Association; 1998:204-10.
5. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19:324-7.
6. Raskin P, Strowig SM, Davidson PC. Benefits of insulin pump therapy. In: The Insulin Pump Therapy Book: Insights from the Experts. Fredrickson L, Ed. Symlar CA: Minimed Technologies; 1995:10-19.
7. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia. 1983;24:326-9.
8. Pickup JC, Keen H, Parson JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. BMJ. 1978;1:204-7.
9. Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of blood glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. 1979;300;573-8.
10. Bruce WB, William V, Tamborlane, Paul CD. Insulin pump therapy in the 21st century. Postgraduate Medicine. 2002;11:2-14.
11. Pickup J and Keen H. Continuous subcutaneous insulin infusion at 25 years. Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593-8.
12. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin Pump Therapy: A meta-analysis. Diabetes Care. 2003;26:1079-87.
13. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with Type 1 diabetes. Diabetes Care. 1999;22:1779-84.
14. Hoogma R. Organising and running a pump service in the Netherlands. Practical diabetes 2001;18(Suppl. 5):7.
15. Knight G. Risks with continuous subcutaneous insulin infusion can be serious. BMJ 2001;323:693-4.
16. Herman WH. Glycemic control in diabetes. BMJ. 1999;319:104-6.
17. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared to intensive insulin injection therapy in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705.
18. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with Type 1 diabetes. Diabetes Care. 1999;22:1779-84.
19. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361-76.
20. Chantelau E, Spraul M, Muhlhauser I, et al: Long-term safety, efficacy, and side effects of continuous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one center experience. Diabetologia. 1989;32:421-6.
21. Kanc K, Jansen MM, Keulen ET, et al. Substitution of night-time continuous subcutaneous insulin therapy for bedtime NPH insulin in a multiple injection regimens improves counterregulatory hormonal responses and warning symptoms of hypoglycemia in IDDM. Diabetologia. 1998;41:322-9.
22. Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications; the perspective of the diabetes control and complications trial. Diabetes. 1996;45:1289-98.
23. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in Type 1 diabetic patients on intensified treatment. Diabetes Care. 2000;23:1232-5.
24. Kaufmaan FR, Halvorson M, Kim C, Pituckcheewanont P. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care. 2000;23:579-82.
25. Couper JJ, Taylor J, Fotheringham MJ, Sawyer M. Failure to maintain the benefits of home-based intervention in adolescents with poorly controlled type 1 diabetes. Diabetes Care. 1999;22:1933-7.
26. Tsui E, Barnie A, Ross S, et al. Intensive therapy with insulin lispro; a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care. 2001;24:1722-7.
27. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26:1142-6.
28. Ahern JH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HBA1C levels across all age groups. Pediatric Diabetes. 2002;3:10-15.
29. de Weerdt I, Visser AP, Kok G, van der Veen EA. Determinants of active self-care behaviour of insulin treated patients with diabetes: implications for diabetes education. Soc Sci Med. 1999;30:605-15.
30. Bott U, Jorgens V, Grusser M, et al. Predictors of glycemic control in type 1 diabetic patients after participation in an intensified treatment and teaching programme. Diabet Med. 1994;11:362-71.
31. Locke DR, Rigg LA. Hypoglycemic coma associated with subcutaneous insulin infusion by portable pump. Diabetes Care. 1981;4:389-91.
32. Bending J, Pickup JC, Keen H. The frequency of diabetic ketoacidosis and hypoglycemia coma during treatment with continuous subcutaneous insulin infusion. Am J Med. 1985;69:685-91.
33. Rudolph JW, Hirsch IB. An assessment on continuous insulin infusion therapy in an academic diabetes clinic. Diabetes. 2000;49(Suppl. 1):501.
34. Home PD, Marshall SM. Problems and safety of continuous subcutaneous insulin infusion. Diabet Med. 1984;1:41-4.
35. Mecklenburg RS, Benson EA, Benson JW, et al. Acute complications associated with insulin pump therapy: report of experience with 161 patients. JAMA. 1984;252:3265-9.
36. Knight J, Jennings AM, Boulton AJM, et al: Severe hyperglycemia and ketoacidosis during routine treatment with an insulin pump. BMJ. 1985;291:371-2.
37. Skyler JS. Lessons from studies of insulin pharmacokinetics. Diabetes Care. 1986;9:666-8 (editorial).
38. Bode BW, Gross TM, Chegan M, et al: Breaking the age barrier: a comparison of continuous subcutaneous insulin infusion in adolescents and adults. Diabetologia. 1999;42(Suppl. 1):227.
39. Steindel B, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995;27;199-204.
40. Blackett P. Insulin pump treatment for recurrent ketoacidosis in adolescence. Diabetes Care. 1995;18:881-2.
41. Knight G, Ward JD. Diabetic ketoacidosis: Lancet. 1986;ii:1284-5.
42. Teush SM, Herman WF, Dweyer D, Lane M. Mortality among diabetic patients using continuous subcutaneous insulin infusion pumps. N Engl J Med. 1984;310:361-8.